Sana Biotechnology

Sana Biotechnology is a Seattle-headquartered company focused on engineering cells as medicines. Its work is organized around three stated aspirations: repairing and controlling genes in any cell in the body (the field classically described as gene therapy), replacing missing or damaged cells using the convergence of stem cell biology and immunology, and building scalable, cost-conscious manufacturing and stakeholder alignment to broaden patient access to the resulting therapies.

The company describes two principal technology areas. Its ex vivo cell replacement work aims to differentiate stem cells into clinically needed cell types—for example pancreatic islet cells for type 1 diabetes—and addresses what Sana frames as the field's core challenges: manufacturing cells at scale and ensuring they engraft, function, and persist, including overcoming immune rejection. Its in vivo Cell Engineering platform targets delivery of payloads (DNA, RNA, proteins) to specific cell types, gene modification (gene editing, base editing, gene insertion, and control of gene expression), and execution in manufacturing and clinical development. Sana states it builds some capabilities internally and partners for others.

Sana's disclosed pipeline focus areas include diabetes, B-cell cancers, and B-cell related autoimmune disorders. The company maintains sites in Seattle (188 East Blaine Street), South San Francisco, and Cambridge, Massachusetts.

Founding story

Sana Biotechnology was founded by former Juno Therapeutics executives Hans Bishop and Steve Harr, along with other executives, and became publicly known on January 4, 2019; the earliest public trace cited is a trademark application filed in August 2018. Harr, previously Juno's chief financial officer, became CEO, and Bishop, previously Juno's CEO, was a co-founder. The company is described as a spin-out from Flagship Pioneering. Harr said he chose Seattle as headquarters to be near talent and the local entrepreneurial environment in gene therapy and cellular engineering, relocating from New York. The founding executive team also included Sunil Agarwal (Chief Development Officer and Head of Portfolio Strategy), Chad Cowan (Chief Scientific Officer), Andy May (Chief Technology Officer), Robin Andrulevich (Chief People Officer), Nate Hardy (Chief Financial Officer), Christian Hordo (Chief Business Officer), and James MacDonald (General Counsel).

Traction

As of mid-2020 the company reported approximately 230 employees across Seattle, San Francisco and Cambridge, of which about 10% came from Juno Therapeutics. It had raised over $700 million in its initial financing (reported as $821 million in SEC filings) and has published platform data in peer-reviewed journals through 2025, including New England Journal of Medicine reports on transplanted allogeneic beta cells.

Latest developments

Publications listed by the company include an August 2025 New England Journal of Medicine paper on survival of transplanted allogeneic beta cells with no immunosuppression, a September 2025 NEJM piece on replacement of beta cells for type 1 diabetes, an October 2025 Nature Reviews Drug Discovery article on in vivo CAR-T cell therapy, and a December 2025 Nature Biotechnology paper on in vivo gene editing of human hematopoietic stem and progenitor cells using envelope-engineered virus-like particles.